Ontology type: schema:ScholarlyArticle Open Access: True
2014-12
AUTHORSValérie Vilgrain, Mohamed Abdel-Rehim, Annie Sibert, Maxime Ronot, Rachida Lebtahi, Laurent Castéra, Gilles Chatellier
ABSTRACTBACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis. While sorafenib is the current recommended treatment for advanced HCC, radioembolisation (RE; also called selective internal radiation therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort studies. However, there are no head-to-head trials comparing radiation therapy with yttrium-90 microspheres and sorafenib in advanced HCC. The SARAH trial has been designed to compare the efficacy and safety of sorafenib therapy and RE using yttrium-90 resin microspheres (SIR-Spheres™; Sirtex Medical Limited, North Sydney, Australia) in patients with advanced HCC. Quality of life (QoL) and cost-effectiveness will also be compared between therapies. METHODS/DESIGN: SARAH is a prospective, randomised, controlled, open-label, multicentre trial comparing the efficacy of RE with sorafenib in the treatment of patients with advanced HCC. The trial aims to recruit adults with a life expectancy of >3 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1, and: advanced HCC according to the Barcelona criteria (stage C) or recurrent HCC after surgical or thermoablative treatment who are not eligible for surgical resection, liver transplantation or thermal ablation; or two rounds of failed chemoembolisation. Patients will be randomised 1:1 to receive either RE or sorafenib 400 mg twice daily. All patients will be monitored for between 12 and 48 months following start of treatment. The primary endpoint of the SARAH trial is overall survival (OS). Secondary endpoints include: adverse events, progression-free survival at 6 months; tumour response rate; general or liver disease-specific QoL scores; and cost of each treatment strategy. Assuming an increase in median OS of 4 months with RE versus sorafenib therapy, randomising at least 400 patients (200 in each treatment arm) will be sufficient for 80% power and a bilateral alpha risk of 5%; therefore, 440 patients will be enrolled to allow for 10% loss of patients due to ineligibility. DISCUSSION: The SARAH trial is the first randomised head-to-head study to compare RE with sorafenib in advanced HCC, and will establish the potential role of RE in HCC treatment guidelines. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01482442, first received 28 November 2011. More... »
PAGES474
http://scigraph.springernature.com/pub.10.1186/1745-6215-15-474
DOIhttp://dx.doi.org/10.1186/1745-6215-15-474
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1037557459
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/25472660
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Carcinoma, Hepatocellular",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Clinical Protocols",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cost-Benefit Analysis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease Progression",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease-Free Survival",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Costs",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Embolization, Therapeutic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "France",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Liver Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Microspheres",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Niacinamide",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Phenylurea Compounds",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Protein Kinase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Quality of Life",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Research Design",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Time Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Yttrium Radioisotopes",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Paris Diderot University",
"id": "https://www.grid.ac/institutes/grid.7452.4",
"name": [
"Department of Radiology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France",
"University Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France, INSERM U1149, Centre de Recherche de l\u2019Inflammation (CRI), 16 rue Henri Huchard, 75018, Paris, France",
"the SARAH trial group, France"
],
"type": "Organization"
},
"familyName": "Vilgrain",
"givenName": "Val\u00e9rie",
"id": "sg:person.0761705775.52",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761705775.52"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Assistance Publique -Hopitaux De Paris",
"id": "https://www.grid.ac/institutes/grid.50550.35",
"name": [
"Department of Radiology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France"
],
"type": "Organization"
},
"familyName": "Abdel-Rehim",
"givenName": "Mohamed",
"id": "sg:person.01013766312.46",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013766312.46"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Assistance Publique -Hopitaux De Paris",
"id": "https://www.grid.ac/institutes/grid.50550.35",
"name": [
"Department of Radiology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France"
],
"type": "Organization"
},
"familyName": "Sibert",
"givenName": "Annie",
"id": "sg:person.0626003100.28",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626003100.28"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Paris Diderot University",
"id": "https://www.grid.ac/institutes/grid.7452.4",
"name": [
"Department of Radiology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France",
"University Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France, INSERM U1149, Centre de Recherche de l\u2019Inflammation (CRI), 16 rue Henri Huchard, 75018, Paris, France"
],
"type": "Organization"
},
"familyName": "Ronot",
"givenName": "Maxime",
"id": "sg:person.01025534354.12",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025534354.12"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Assistance Publique -Hopitaux De Paris",
"id": "https://www.grid.ac/institutes/grid.50550.35",
"name": [
"Department of Nuclear Medicine, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 100 boulevard General Leclerc, 92118, Hauts-de-Seine, Clichy, France"
],
"type": "Organization"
},
"familyName": "Lebtahi",
"givenName": "Rachida",
"id": "sg:person.0621226525.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621226525.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Paris Diderot University",
"id": "https://www.grid.ac/institutes/grid.7452.4",
"name": [
"Department of Hepatology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 100 boulevard General Leclerc, 92118, Hauts-de-Seine, Clichy, France",
"University Paris Diderot, Sorbonne Paris Cit\u00e9, 5 rue Thomas Mann, 75013, Paris, France"
],
"type": "Organization"
},
"familyName": "Cast\u00e9ra",
"givenName": "Laurent",
"id": "sg:person.0631670105.90",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631670105.90"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Paris Descartes University",
"id": "https://www.grid.ac/institutes/grid.10992.33",
"name": [
"Assistance Publique, H\u00f4pitaux de Paris, APHP, H\u00f4pital Europ\u00e9en Georges Pompidou, URC, 20 rue Leblanc, 75015, Paris, France",
"INSERM, Centre d\u2019Investigation \u00c9pid\u00e9miologique 4 (CIE4), 80 rue Lecourbe, 75015, Paris, France",
"Sorbonne Paris Cit\u00e9, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Descartes, 12 rue de l'Ecole de M\u00e9decine, 75006, Paris, France"
],
"type": "Organization"
},
"familyName": "Chatellier",
"givenName": "Gilles",
"id": "sg:person.0610327425.04",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610327425.04"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1053/j.gastro.2009.09.006",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003442138"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/lt.22434",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003964451"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/hep.21980",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012076894"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00280-011-1753-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012147791",
"https://doi.org/10.1007/s00280-011-1753-2"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.cct.2009.08.002",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1012763140"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00280-009-1226-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014381903",
"https://doi.org/10.1007/s00280-009-1226-z"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00280-009-1226-z",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014381903",
"https://doi.org/10.1007/s00280-009-1226-z"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1634/theoncologist.2013-0114",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014890838"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/jso.20609",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017230735"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.critrevonc.2013.12.013",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018387939"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1470-2045(08)70285-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018829845"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/hep.23944",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019162732"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/hep.23944",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019162732"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.jvir.2007.07.016",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1021011178"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00330-008-1211-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1024345371",
"https://doi.org/10.1007/s00330-008-1211-7"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ijrobp.2006.05.065",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028312901"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1470-2045(08)70003-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031125262"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/jnci/92.3.205",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032301848"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1001/jama.2010.1672",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033887880"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0168-8278(09)60780-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035571428"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1053/j.gastro.2008.02.090",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038242669"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1159/000343091",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038427252"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2011.37.1021",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041287255"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ijrobp.2009.06.069",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042012604"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/hep.24451",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042501738"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1994.436",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042684896",
"https://doi.org/10.1038/bjc.1994.436"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1994.436",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042684896",
"https://doi.org/10.1038/bjc.1994.436"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/hep.26014",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1044188627"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ejca.2004.06.033",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045614635"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1634/theoncologist.2010-s4-05",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047436237"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0360-3016(97)00818-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050128451"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/jnci/djn134",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050426018"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.jhep.2011.12.001",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051138497"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa0708857",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1053513212"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.2307/2532572",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1069977982"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3892/etm.2012.569",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1071503303"
],
"type": "CreativeWork"
}
],
"datePublished": "2014-12",
"datePublishedReg": "2014-12-01",
"description": "BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis. While sorafenib is the current recommended treatment for advanced HCC, radioembolisation (RE; also called selective internal radiation therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort studies. However, there are no head-to-head trials comparing radiation therapy with yttrium-90 microspheres and sorafenib in advanced HCC. The SARAH trial has been designed to compare the efficacy and safety of sorafenib therapy and RE using yttrium-90 resin microspheres (SIR-Spheres\u2122; Sirtex Medical Limited, North Sydney, Australia) in patients with advanced HCC. Quality of life (QoL) and cost-effectiveness will also be compared between therapies.\nMETHODS/DESIGN: SARAH is a prospective, randomised, controlled, open-label, multicentre trial comparing the efficacy of RE with sorafenib in the treatment of patients with advanced HCC. The trial aims to recruit adults with a life expectancy of >3 months, Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1, and: advanced HCC according to the Barcelona criteria (stage C) or recurrent HCC after surgical or thermoablative treatment who are not eligible for surgical resection, liver transplantation or thermal ablation; or two rounds of failed chemoembolisation. Patients will be randomised 1:1 to receive either RE or sorafenib 400 mg twice daily. All patients will be monitored for between 12 and 48 months following start of treatment. The primary endpoint of the SARAH trial is overall survival (OS). Secondary endpoints include: adverse events, progression-free survival at 6 months; tumour response rate; general or liver disease-specific QoL scores; and cost of each treatment strategy. Assuming an increase in median OS of 4 months with RE versus sorafenib therapy, randomising at least 400 patients (200 in each treatment arm) will be sufficient for 80% power and a bilateral alpha risk of 5%; therefore, 440 patients will be enrolled to allow for 10% loss of patients due to ineligibility.\nDISCUSSION: The SARAH trial is the first randomised head-to-head study to compare RE with sorafenib in advanced HCC, and will establish the potential role of RE in HCC treatment guidelines.\nTRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01482442, first received 28 November 2011.",
"genre": "research_article",
"id": "sg:pub.10.1186/1745-6215-15-474",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1297400",
"issn": [
"1468-6708",
"1745-6215"
],
"name": "Trials",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "15"
}
],
"name": "Radioembolisation with yttrium\u201290 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial",
"pagination": "474",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"b2e8fa22607d0fae3de7bcc9a5fdc2ed944f26b055bbf955cdb59a9651ae6620"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"25472660"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101263253"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/1745-6215-15-474"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1037557459"
]
}
],
"sameAs": [
"https://doi.org/10.1186/1745-6215-15-474",
"https://app.dimensions.ai/details/publication/pub.1037557459"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T14:10",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000514.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1186%2F1745-6215-15-474"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-474'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-474'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-474'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-474'
This table displays all metadata directly associated to this object as RDF triples.
311 TRIPLES
21 PREDICATES
83 URIs
42 LITERALS
30 BLANK NODES